Apoptosis by p53: Mechanisms, regulation, and clinical implications

Springer Seminars in Immunopathology

Volumn 19, Issue 3, 1998, Pages 345-362

  Sionov, Ronit Vogt ^a   Haupt, Ygal ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADENOVIRUS; APOPTOSIS; CANCER CHEMOTHERAPY; CELL CYCLE; CELL DEATH; GENE EXPRESSION REGULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

APOPTOSIS; GENES, P53; HUMANS;

EID: 0031882549     PISSN: 03444325     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00787230     Document Type: Review

References (104)

1. Aas T, Børresen A-L, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA, Lønning PE (1996) Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811
2. Abarzúa P, LoSardo JE, Gubler ML, Neri A (1995) Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Res 55: 3490
3. Adams PD, Kaelin WG Jr (1996) The cellular effects of E2F overexpression. Curr Top Microbiol Immunol 208: 79
4. Arrowsmith CH, Morin P (1996) New insights into p53 function from structural studies. Oncogene 12: 1379
5. Attardi LD, Lowe SW, Brugarolas J, Jacks T (1996) Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J 15: 3693
6. Avantaggiata ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K (1997) Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89: 1175
7. Bates S, Vousden KH (1996) p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev 6: 12
8. Beaudry GA, Bertelsen AH, Sherman MI (1996) Therapeutic targeting of the p53 tumor suppressor gene. Curr Opin Biotechnol 7: 592
9. Blaydes JP, Gire V, Rowson JM, Wynford-Thomas D (1997) Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by Mdm-2. Oncogene 14: 1859
10. Böttger V, Böttger A, Howard SF, Picksley SM, Chène P, Garcia-Echeverria C, Hochkeppel H-K, Lane DP (1996) Identification of novel mdm2 binding peptides by phage display. Oncogene 13: 2141
11. Brady HJM, Salomons GS, Bobeldijk RC, Berns AJM (1996) T cells from baxα transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53. EMBO J 15: 1221
12. Caliskan M, Türkeri LN, Mansuroglu B, Toktas G, Aksoy B, Ünlüer E, Akdas A (1997) Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer. Br. J Urol 79: 373
13. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B, Slamon DJ (1996) DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13: 1971
14. Chandler JM, Alnemri ES, Cohen GM, MacFarlane M (1997) Activation of CPP32 and Mch3α in wild-type p53-induced apoptosis. Biochem J 322: 19
15. Chen HL, Carbone DP (1997) p53 as a target for anti-cancer immunotherapy. Mol Med Today 3: 160
16. 1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 16: 2445
17. Chen X, Ko LJ, Jayaraman L, Prives C (1996) p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 10: 2438
18. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF, Levine AJ (1994) Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54: 794
19. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH, Reid BJ (1995) A p53-dependent mouse spindle checkpoint. Science 267: 1353
20. Del Sal G, Ruaro EM, Utrera R, Cole CN, Levine AJ, Schneider C (1995) Gas1-induced growth suppression requires a transactivation-independent p53 function. Mol Cell Biol 15: 7152
21. Dou QP, Lui VWY (1995) Failure to dephosphorylate retinoblastoma protein in drug-resistant cells. Cancer Res 55: 5222
22. Flaman J-M, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino A-P, Limacher J-M, Bron L, Benhattar J, Tada M, Van Meir EG, Estreicher A, Iggo RD (1995) A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 92: 3963
23. Fontanini G, Vignati S, Lucchi M, Mussi A, Calcinai A, Boldrini L, Chiné S, Silvestri V, Angeletti CA, Basolo F, Bevilacqua G (1997) Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br J Cancer 75: 1295
24. Friedlander P, Haupt Y, Prives C, Oren M (1996) A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 16: 4961
25. Friesen C, Herr I, Krammer PH, Debatin K-M (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 2: 574
26. Waf1/Cip1 protects against p53-mediated apoptosis of human melanoma cells. Oncogene 14: 929
27. Gottlieb TM, Oren M (1996) p53 in growth control and neoplasia. Biochim Biophys Acta 1287: 77
28. Guillouf C, Graña X, Selvakumaran M, De Luca A, Giordano A, Hoffman B, Liebermann DA (1995) Dissection of the genetic programs of p53-mediated G1 growth arrest and apoptosis: blocking p53-induced apoptosis unmasks G1 arrest. Blood 85: 2691
29. Hall PA, Lane DP (1997) Tumour suppressors: a developing role for p53. Curr Biol 7: R144
30. Hall PA, Meek D, Lane DP (1996) p53 - integrating the complexity. J Pathol 180: 1
31. Hamada K, Sakaue M, Alemany R, Zhang W-W, Horio Y, Roth JA, Mitchell MF (1996) Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. Gynecol Oncol 63: 219
32. Hansen R, Oren M (1997) p53; from inductive signal to cellular effect. Curr Opin Genet Dev 7: 46
33. Hansen RS, Braithwaite AW (1996) The growth-inhibitory function of p53 is separable from transactivation, apoptosis and suppression of transformation by E1a and Ras. Oncogene 13: 995
34. Harris CC (1996) Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88: 1442
35. Haupt Y, Oren M (1996) p53-mediated apoptosis: mechanisms and regulation. Behring Inst Mitt 97: 32
36. Haupt Y, Rowan S, Oren M (1995) p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene 10: 1563
37. Haupt Y, Rowan S, Shaulian E, Vousden KH, Oren M (1995) Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 9: 2170
38. Haupt Y, Barak Y, Oren M (1996) Cell type-specific inhibition of p53-mediated apoptosis by Mdm2. EMBO J 15: 1596
39. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296
40. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3: 639
41. Hollstein M, Soussi T, Thomas G, von Brevern M-C, Bartsch H (1997) p53 gene alterations in human tumors: perspectives for cancer control. Recent Results Cancer Res 143: 369
42. Hupp TR, Sparks A, Lane DP (1995) Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83: 237
43. Ilan Y, Droguett G, Chowdhury NR, Li Y, Sengupta K, Thummala NR, Davidson A, Chowdhury JR, Horwitz MS (1997) Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci USA 94: 2587
44. Israeli D, Tessler E, Haupt Y, Elkeles A, Wilder S, Amson R, Telerman A, Oren M (1997) A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. EMBO J 16: 4384
45. Knippschild U, Oren M, Deppert W (1996) Abrogation of wild-type p53 mediated growth-inhibition by nuclear exclusion. Oncogene 12: 1755
46. Ko LJ, Prives C (1996) p53: puzzle and paradigm. Genes Dev 10: 1054
47. Kondo S, Barnett GH, Hara H, Morimura T, Takeuchi J (1995) Mdm2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 10: 2001
48. Kroemer G (1997) The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 3: 614
49. Kubbutat MHG, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387: 299
50. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323
51. Levine AJ, Wu MC, Chang A, Silver A, Attiyeh EF, Lin J, Epstein CB (1995) The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype. Ann N Y Acad Sci 768: 111
52. Lin J, Chen J, Elenbaas B, Levine AJ (1994) Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to Mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 8: 1235
53. Lomax ME, Barnes DM, Gilchrist R, Picksley SM, Varley JM, Camplejohn RS (1997) Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family. Oncogene 14: 1869
54. Ludwig RL, Bates S, Vousden KH (1996) Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 16: 4952
55. Maheswaran S, Englert C, Bennett P, Heinrich G, Haber DA (1995) The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev 9: 2143
56. Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB (1996) Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 183: 1357
57. Menke AL, Shvarts A, Riteco N, van Ham RCA, van der Eb AJ, Jochemsen AG (1997) Wilms' tumor 1-KTS isoforms induce p53-independent apoptosis that can be partially rescued by expression of the epidermal growth factor receptor or the insulin receptor. Cancer Res 57: 1353
58. Miyashita T, Harigai M, Hanada M, Reed JC (1994) Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54: 3131
59. Montes de Oca Luna R, Wagner DS, Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203
60. Morgan SE, Kastan MB (1997) p53 and ATM: Cell cycle, cell death and cancer. Adv Cancer Res 71: 1
61. Murphy M, Hinman A, Levine AJ (1996) Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev 10: 2971
62. Nakanishi H, Ohsawa M, Naka N, Uchida A, Ochi T, Aozasa K (1997) Immunohistochemical detection of Bcl-2 and p53 proteins and apoptosis in soft tissue sarcoma: their correlations with prognosis. Oncology 54: 238
63. 2/M. Mol Cell Biol 16: 3884
64. Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA (1996) Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 112: 1372
65. Nguyen DM, Wiehle SA, Roth JA, Cristiano RJ (1997) Gene delivery into malignant cells in vivo by a conjugated adenovirus/DNA complex. Cancer Gene Ther 4: 183
66. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang W-W, Kruzel E, Radinsky R (1995) Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15: 3032
67. Perry ME, Piette J, Zawadzki JA, Harvey D, Levine AJ (1993) The mdm2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci USA 90: 11623
68. Picksley SM, Lane DP (1993) The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays 15: 689
69. Prisco M, Hongo A, Rizzo MG, Sacchi A, Baserga R (1997) The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal. Mol Cell Biol 17: 1084
70. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M (1997) Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275: 967
71. Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E, Levine AJ (1996) p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci USA 93: 4781
72. Roth JA, Cristiano RJ (1997) Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 89: 21
73. Roth JA, Nguyen D, Lawrence DD, et al (1996) Retrovirus-mediated wild-type p53 gene transfer to tumors of patients w ith lung cancer. Nat Med 2: 985
74. Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M, Vousden KH (1996) Specific loss of apoptotic hut not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 15: 827
75. Ryan JJ, Danish R, Gottlieb CA, Clarke MF (1993) Cell cycle analysis of p53-induced cell death in murinc erythroleukemia cells. Mol Cell Biol 13: 711
76. Sabbatini P, Lin J, Levine AJ, White E (1995) Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes Dev 9: 2184
77. INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 3: 313
78. Selivanova G, Iotsova V, Okan I, Fritsche M, Ström M, Groner B, Grafström RC, Wiman KG (1997) Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 3: 632
79. Shafman T, Khanna KK, Kedar P, Spring K, Kozlov S, Yen T, Hobson K, Gatei M, Zhang N, Watters D, Egerton M, Shiloh Y, Kharbanda S, Kufe D, Lavin MF (1997) Interaction between ATM protein and c-Abl in response to DNA damage. Nature 387: 520
80. Shelling AN (1997) Role of p53 in drug resistance in ovarian cancer. Lancet 349: 744
81. Shen Y, Shenk TE (1995) Viruses and apoptosis. Curr Opin Genet Dev 5: 105
82. Sherr CJ (1996) Cancer cell cycles. Science 274: 1672
83. Sidransky D, Hollstein M (1996) Clinical implications of the p53 gene. Annu Rev Med 47: 285
84. Silvestrini R, Veneroni S, Benini E, Daidone MG, Luisi A, Leutner M, Maucione A, Kenda R, Zucali R, Veronesi U (1997) Expression of p53, glutathione S-transferase-π, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst 89: 639
85. Soussi T (1996) The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. Immunol Today 17: 354
86. Steegenga WT, van der Eb AJ, Jochemsen AG (1996) How phosphorylation regulates the activity of p53. J Mol Biol 263: 103
87. Sun X-F, Johannsson O, Håkansson S, Sellberg G, Nordenskjöld B, Olsson H, Borg A (1996) A novel p53 germline alteration identified in a late onset breast cancer kindred. Oncogene 13: 407
88. Symonds H, Chen JD, Van Dyke T (1991) Complex formation between the lymphotropic papovavirus large tumor antigen and the tumor suppressor protein p53. J Virol 65: 5417
89. Teodoro JG, Branton PE (1997) Regulation of apoptosis by viral gene products. J Virol 71: 1739
90. Theobald M, Biggs J, Hernúndez, J, Lustgarten J, Labadie C, Sherman LA (1997) Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 185: 833
91. Velculescu VE, El-Deiry WS (1996) Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 42: 858
92. Wagner RW, Flanagan WM (1997) Antisense technology and prospects for therapy of viral infections and cancer. Mol Med Today 3: 31
93. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2: 72
94. Walker KK, Levine AJ (1996) Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA 93: 15335
95. 2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 88: 956
96. Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K, Xu G, Elmore L, Yeh H, Hoeijmakers JHJ, Harris CC (1996) The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev 10: 1219
97. Wen S-T, Jackson PK, Van Etten RA (1996) The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products. EMBO J 15: 1583
98. White E (1996) Life, death, and the pursuit of apoptosis. Genes Dev 10: 1
99. Xu L, Pirollo KF, Chang EH (1997) Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro. Hum Gene Ther 8: 467
100. Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T (1997) Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385: 637
101. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M (1991) Wild-type p53 induces apoptosis of myeloid leukaemis cells that is inhibited by interleukin-6. Nature 352: 345
102. Yonish-Rouach E, Choisy C, Deguin V, Breugnot C, May E (1996) The role of p53 as a transcription factor in the induction of apoptosis. Behring Inst Mitt 97: 60
103. Yuan Z-M, Huang Y, Whang Y, Sawyers C, Weichselbaum R, Kharbanda S, Kufe D (1996) Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature 382: 272
104. Yuan Z-M, Huang Y, Ishiko T, Kharbanda S, Weichselbaum R, Kufe D (1997) Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase. Proc Natl Acad Sci USA 94: 1437